Junsheng Li

Dr. Junsheng Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JLJunsheng Li
Junsheng Li
QZQian Zhang
Qian Zhang
WWWen Wang
Wen Wang
FLFa Lin
Fa Lin
SWShuo Wang
Shuo Wang
JZJizong Zhao
Jizong Zhao

14 January 2020 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
WWWen Wang
Wen Wang
JLJunsheng Li
Junsheng Li
FLFa Lin
Fa Lin
JGJia Guo
Jia Guo
JZJizong Zhao
Jizong Zhao

22 November 2020 in Disease Markers
Verified
Journal Article
Open access
JLJunsheng Li
Junsheng Li
QZQian Zhang
Qian Zhang
PGPeicong Ge
Peicong Ge
CZChaofan Zeng
Chaofan Zeng
FLFa Lin
Fa Lin
JZJizong Zhao
Jizong Zhao
FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma: Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs ( ). The expression of FAM225B increased with the grades of gliomas ( ). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group ( ). Similar result was found in the training set ( ) and verified in the validation set ( ). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs ( ). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. Conclusions. FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.

15 September 2023 in European Polymer Journal
Verified
Journal Article
Closed access
HZHaifeng Zhang
Haifeng Zhang
YSYun Shao
Yun Shao
BGBingbing Gao
Bingbing Gao
JLJunsheng Li
Junsheng Li

1 May 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
WWWen Wang
Wen Wang
JLJunsheng Li
Junsheng Li
FLFa Lin
Fa Lin
JGJia Guo
Jia Guo
JZJizong Zhao
Jizong Zhao

14 May 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
JLJunsheng Li
Junsheng Li
QHQiheng He
Qiheng He
CLChenglong Liu
Chenglong Liu
CZChaofan Zeng
Chaofan Zeng
CTChuming Tao
Chuming Tao
JZJizong Zhao
Jizong Zhao
Objective: The role of methionine (Met) cycle in the pathogenesis and progression of cardiovascular and cerebrovascular diseases has been established, but its association with moyamoya disease (MMD) has rarely been studied. This study aimed to analyze the levels of Met cycle‐related metabolites and constructed a risk model to explore its association with the risk of MMD.Methods: In this prospective study, a total of 302 adult MMD patients and 88 age‐matched healthy individuals were consecutively recruited. The serum levels of Met cycle‐related metabolites were quantified by liquid chromatography‐mass spectrometry (LC–MS). Participants were randomly divided into training set and testing set at a ratio of 1:1. The training set was used to construct the risk score model by LASSO regression. The association between Met cycle‐related risk score and the risk of MMD was analyzed using logistic regression and assessed by ROC curves. The testing set was used for validation.Results: The levels of methionine sulfoxide and homocysteine were significantly increased, while the levels of betaine and choline were significantly decreased in MMD and its subtypes compared to healthy controls (p < 0.05 for all). The training set was used to construct the risk model and the risk score of each participant has been calculated. After adjusting for potential confounders, the risk score was independently associated with the risk of MMD and its subtypes (p < 0.05 for all). We then divided the participants into low‐risk and high‐risk groups, the high‐risk score was significantly associated with the risk of MMD and its subtypes (p < 0.05 for all). The risk scores were further assessed as tertiles, the highest tertile was significantly associated with a higher risk of MMD and its subtypes compared to the lowest (p < 0.05 for all). The results were validated in the testing set.Conclusion: This study has constructed and validated a risk model based on Met cycle‐related metabolites, which was independently associated with the risk of MMD and its subtypes. The findings provided a new perspective on the risk evaluation and prevention of MMD.